Navigation Links
Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Date:2/1/2008

itigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the effect of the completion of the Phase 2 clinical trial for Amigal for the treatment of Fabry disease, the plans for the Phase 3 clinical trial for Amigal, the Phase II clinical trials for Plicera(TM) for the treatment of Gaucher disease, and the effect of the completion of the Phase I clinical trials for AT2220 for the treatment of Pompe disease may not proceed in the timeframes or in the manner Amicus expects or at all. Further, the results of earlier clinical trials may not be predictive of future results; Amicus and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks detailed in the public filings of Amicus with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. All forward-looking statements are
'/>"/>
SOURCE Amicus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
2. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
3. Amicus Therapeutics to Host R&D Day
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
6. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
7. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
8. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
9. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
10. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
11. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)...  Today, Americord Registry, one of the fastest growing cord ... a partner at Kirkland & Ellis LLP, as the newest ... http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are thrilled about ... Martin Smithmyer , CEO of Americord. "He brings a wealth ... assist Americord,s growth and vision." Andrew Horne ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... that does not sacrifice selectivity to achieve faster flow rates in comparison to ... pores with significant open space to allow easy liquid flow while trapping particulates ...
(Date:6/30/2015)... ... June 30, 2015 , ... The maximum number of shares proposed to ... shares (including shares of unvested restricted stock). On June 29, 2015, the last trading ... Cryo-Cell’s shares reported on the OTCBB was $2.29 per share. , The tender offer ...
(Date:6/30/2015)... 30, 2015  The University of California, San ... and UC San Diego Extension announced their third ... Aug.  12 – 14, 2015, at UC San ... provides an intense exposure to best practices and ... well-suited to biologists, process engineers and business executives ...
Breaking Biology Technology:Americord Registry Announces Andrew Horne as Advisory Board Member 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2
... 2011 Sangamo BioSciences, Inc. (Nasdaq: SGMO ) ... of 6,700,000 shares of its common stock at a price ... is expected to close on or around Wednesday, April 13, ... the sole book-running manager in this offering and Sangamo has ...
... RICHMOND, Calif., April 7, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... to sell 6,700,000 shares of its common stock pursuant to ... Barclays Capital Inc. is the sole book-running manager in this ... day option to purchase up to 1,005,000 additional shares. ...
... The Center for Business Intelligence (CBI) announced today that ... in support of the relief efforts in Japan following a ... the fund while the organization matched employee donations. ... employees have displayed to help a nation in a desperate ...
Cached Biology Technology:Sangamo Announces Pricing of Public Offering of Common Stock 2Sangamo Announces Pricing of Public Offering of Common Stock 3Sangamo Announces Public Offering of Common Stock 2Sangamo Announces Public Offering of Common Stock 3The Center for Business Intelligence Donates to the American Red Cross, Matching Employee Contributions for Disaster Relief in Japan 2
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland , ... ®   Produktlinie mit DNA-Tests verbessert ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... neue STR-Testkits der Produktlinie Investigator ® ... den Markt eingeführt. Die neuen Kits zur Erstellung genetischer ...
(Date:6/16/2015)... 2015 /CNW Telbec/ - handyem Inc. and FlowMetric ... incorporation of handyem,s HPC-150 portable flow cytometer within ... This unprecedented model of mobile laboratory platform is ... Pennsylvania Convention Center, ... to 18 th 2015.  By virtue ...
(Date:6/15/2015)... 2015 According to a new ... (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern ... by MarketsandMarkets, The Natural Language Processing Market is expected ... 18.4% for the forecast period 2015-2020. ... igures spread   through 155 P ages ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
... Southern Medical University in Guangdong, Guangzhou, China, have developed ... bacteria responsible for peptic ulcers and some forms of ... The research is published ahead of print in the ... The investigators constructed a live recombinant bacterial vaccine, expressing ...
... lung damage and adrenal hormone abnormalities not previously seen ... study published Dec. 18, 2013 in the journal ... spill heavily oiled Barataria Bay. The study was conducted ... Damage Assessment (NRDA) by a team of government, academic ...
... BELL, Pa. , Dec. 19, 2013 Security experts ... today predicted that the coming year will usher in broad-based ... unencrypted data traffic inside enterprises is vulnerable to detection from ... accessed data from the internal networks of major internet service ...
Cached Biology News:H. pylori vaccine shows promise in mouse studies 2Deepwater Horizon NRDA study shows possible oil impact on dolphins 2Deepwater Horizon NRDA study shows possible oil impact on dolphins 3Unisys Security Experts Predict 2014 Will Be "The Year of Encryption" as Organizations Combat Growing Cyber Threats 2Unisys Security Experts Predict 2014 Will Be "The Year of Encryption" as Organizations Combat Growing Cyber Threats 3Unisys Security Experts Predict 2014 Will Be "The Year of Encryption" as Organizations Combat Growing Cyber Threats 4
...
Rat polyclonal to Vitamin B3 ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule, Vitamin B3 conjugated to BSA....
Request Info...
Amyloid stain....
Biology Products: